Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DaiS who wrote (18114)	1/25/1999 7:50:00 AM
From: BigKNY3	Read Replies (1) \| Respond to of 23519

Lipitor reaches $2.2 billion in second year WLA has reported 4 Qt earnings and 1998 Lipitor sales this am. BigKNY3 Pharmaceutical sales growth was led by Lipitor (atorvastatin calcium). Worldwide sales of Lipitor more than doubled to $2.2 billion in 1998. Lipitor continues to be the most prescribed cholesterol-lowering agent in the U.S., holding a 38 percent share of new prescriptions in the cholesterol-lowering market. In November, the landmark AVERT trial results (atorvastatin versus revascularization treatments) demonstrated that in addition to lowering cholesterol, treatment with Lipitor may also help patients delay the need for cardiac procedures such as coronary angioplasty.